ChemDiv Inc., a fully integrated CRO, has entered into a three-way co-development agreement with Context Therapeutics and Torrey Pines Investment to advance research and development in the area of Sigma1 dysfunction associated with early onset neurodegenerative diseases. Under the agreement, ChemDiv grants Context access to its integrated discovery platform, while Torrey Pines will invest in Context and provide network resources to support pre-commercial R&D.

This collaboration will allow ChemDiv to capitalize on its resources and experience in drug discovery to help Context expand its pipeline of treatments against Sigma1 mutations that are associated with severe early onset neurodegenerative diseases, such as ALS and Alzheimer’s.

“Sigma1 provides a very exciting new R&D target that could offer an alternative to those patients whose needs cannot be met with existing treatments,” said Martin Lehr, co-founder and chief executive officer at Context Therapeutics. “We are looking forward to the fruits of this collaboration, and hope that our collective efforts will streamline the development of a potent cure for Sigma1 associated neurodegenerative diseases around the globe.”